TY - JOUR T1 - Response to: Comment on l’Ami <em>et al</em> titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2017-212602 SP - annrheumdis-2017-212602 AU - Merel J l’Ami AU - Charlotte L M Krieckaert AU - Michael T Nurmohamed AU - Ronald F van Vollenhoven AU - Theo Rispens AU - Maarten Boers AU - Gerrit Jan Wolbink Y1 - 2017/11/11 UR - http://ard.bmj.com/content/early/2017/11/13/annrheumdis-2017-212602.abstract N2 - We thank den Broeder et al for their interest in our study and for their suggestions concerning further research.1 Our study did not target the broad issue of dose tapering, but focused on the population of patients with rheumatoid arthritis with high adalimumab concentrations (&gt;8 µg/mL).2 We hypothesised that given the wide variation in serum concentrations on standard dosing and the established plateau in the concentration–response relationship—even in active disease3—there would be a role for individualised dosing to optimise adalimumab therapy. Unlike den Broeder et al, we find nothing peculiar about our research question or design … ER -